Abstract
Infection with SARS-CoV-2 virus is associated with a wide range of symptoms. The REal-time Assessment of Community Transmission -1 (REACT-1) study has been monitoring the spread and clinical manifestation of SARS-CoV-2 among random samples of the population in England from 1 May 2020 to 31 March 2022. We show changing symptom profiles associated with the different variants over that period, with lower reporting of loss of sense of smell and taste for Omicron compared to previous variants, and higher reporting of cold-like and influenza-like symptoms, controlling for vaccination status. Contrary to the perception that recent variants have become successively milder, Omicron BA.2 was associated with reporting more symptoms, with greater disruption to daily activities, than BA.1. With restrictions lifted and routine testing limited in many countries, monitoring the changing symptom profiles associated with SARS-CoV-2 infection and induced changes in daily activities will become increasingly important.
A meta-analysis of studies from the first wave of the pandemic identified 30 symptoms reported in multiple studies,1 including common influenza-like symptoms (cough, fever, myalgia/fatigue, headache, sputum production), and less common but more specific symptoms including change or loss of sense of smell and taste.
Previous community-based studies have assessed the degree to which symptom data can predict polymerase chain reaction (PCR) positivity for SARS-CoV-2, and have used variable selection and ranking techniques to identify the most important (set of) symptoms for case identification.2– 4 Further studies have indicated that symptom profiles may differ between variants of SARS-CoV-2.5–7
The relationship between symptom profile and cycle threshold (Ct) value from PCR testing (an established proxy for viral load,8–10 which in turn correlates with infectiousness11,12) has also yet to be fully investigated. Identifying individuals who are more likely to be i) infected, and ii) infectious on the basis of symptom profile would have clinical value as governments move away from mass testing programmes and mandatory isolation measures.
Here, we use regression modelling and variable selection models in the large community-based REal-time Assessment of Community Transmission -1 (REACT-1) study that was in the field approximately monthly from 1 May 2020 to 31 March 2022 to i) describe the symptom profiles of the main variants of SARS-CoV-2 that have been dominant in England and worldwide since May 2020, namely wild-type, Alpha, Delta and Omicron BA.1 and BA.2, and ii) identify the symptoms that are most predictive of high viral load, and hence infectiousness, for each variant.
Methods
Study population
The REACT-1 study has been tracking the prevalence of SARS-CoV-2 in the general population of England. The study protocol and methodology have been published in detail;2,13 briefly, every 4–6 weeks, recruitment letters were sent to a random, nationally representative sample of people aged 5 years and over in England, using the National Health Service patient register. Participants then obtained self-administered throat and nasal swabs for SARS-CoV-2 PCR testing and completed an online or telephone questionnaire which included questions on demographic variables, behaviour, and recent symptoms. Questionnaires for each of the 19 completed rounds since May 2020 are available on the study website (https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/for-researchers/react-1-study-materials/). Between 95,000 and 175,000 viable swabs and valid responses were gathered each round, with respondents unaware of their test result at the time of their response.
Participants were asked whether they experienced any of a list of 26 potential COVID-19 symptoms in the week prior to their test. These included loss or change of sense of smell or taste, respiratory/cardiac symptoms (new persistent cough, chest pain, tight chest, shortness of breath), cold-like symptoms (runny nose, blocked nose, sneezing, sore throat, hoarse voice, sore eyes), influenza-like symptoms (fever, chills, muscle aches, headache), gastrointestinal symptoms (nausea/vomiting, abdominal pain/belly ache, diarrhoea, appetite loss), fatigue-related symptoms (tiredness, severe fatigue, difficulty sleeping), and others (dizziness, heavy arms or legs, numbness/tingling).
We use data from 15 rounds of REACT-1 between 19 June 2020 and 31 March 2022 into distinct phases that correspond with the dominance of different SARS-CoV-2 variants in England: rounds 2–7 (at approximately monthly intervals between 19 June and 3 December 2020), when wild-type was dominant; rounds 8–10 (between 6 January and 29 March 2021), when Alpha (B.1.1.7) was dominant; rounds 13–15 (between 24 June and 5 November 2021), when Delta (B.1.617.2) was dominant; and rounds 17–19 (between 5 January and 31 March 2022), when Omicron (B.1.1.529) was dominant. In rounds 17–19 we use sequencing data to identify those participants who were infected with BA.1 or BA.2. Round 1 is excluded because the symptom questions asked were not consistent with subsequent rounds. Rounds 11, 12 and 16 are excluded from analysis because they occurred at times when two variants were competing for dominance in the population.14
Adults aged 18 years and over were included in the analysis. A total of 266,847 participants were excluded because of missing symptom data, and 38 were excluded because of missing age or sex data resulting in a final study population, after exclusions, of 1,542,510 participants.
Statistical analyses
We used univariable logistic regression models to estimate the risk of PCR swab-positivity for each variant conditional on experiencing each of the 26 symptoms. Models were adjusted on age group, sex, and self-reported vaccination status (coded as the number of vaccines received). Odds ratios and 95% confidence intervals are reported for each symptom and each variant.
Variable selection models were trained on 70% of the data set, with 30% held back for model performance evaluation (see Supplementary Methods). We used stability selection applied to least absolute shrinkage and selection operator (LASSO) penalised logistic regression, with swab positivity as the binary outcome variable, and the 26 symptoms as predictors. To adjust for age, sex and vaccination status, these were included in the models as unpenalised variables. The regression coefficients for selected symptoms were constrained to non-negative values. LASSO models were fit on 1000 random 50% subsamples of the 70% training data. The proportion of models in which each symptom was selected is taken as a measure of variable importance. The threshold in selection proportion for final variable selection was calibrated in conjunction with the LASSO penalty parameter using an internal stability score.15
BA.1 vs BA.2
Omicron BA.1 and BA.2 lineages were determined using viral genome sequencing on swab-positive swabs from rounds 17–19. We compared the symptom profiles in (BA.1 or BA.2) swab-positive individuals using logistic regression with BA.2 vs BA.1 as the binary outcome variable and each of the 26 symptoms as explanatory variables, adjusted on age group, sex, vaccination status and round. As a sensitivity analysis, we 1:1 matched swab-positive participants with BA.1 and BA.2 on age group (+/-5 years), sex, vaccination status and round in rounds 17–19, and conducted conditional logistic regression with BA.2 vs BA.1 as the binary outcome variable.
Severity of symptoms
To assess whether there are differences in symptom severity between BA.1 and BA.2 independent of vaccination history we took a subset of swab-positive individuals with sequence-confirmed BA.1 or BA.2 who had received booster (third) vaccines at least two weeks before their PCR test. In this group, we compared the risk of reporting symptoms that affected their daily activities ‘a lot’ vs ‘a little’ or ‘not at all’ in people infected with BA.1 vs BA.2.
We adjusted for age, sex, days since booster (including a squared polynomial term), and round.
Ct values
Finally, we investigated the relationship between N-gene Ct value and symptom profile among swab positive individuals in rounds 17–19 (>95% Omicron), using linear regression models with Ct value as the outcome variable and each symptom separately as the independent variable. We also compared Ct values between swab-positive individuals with BA.1 and BA.2 using an unpaired Wilcoxon test.
Results
Descriptive and univariable analysis
The characteristics of our study population are summarised in Figure 1 and Supplementary Tables 1 and 2. We included a total of 17,448 swab positive individuals: 2,971 (0.4% [0.4,0.4] unweighted prevalence) for wild,type; 2,275 (0.6% [0.6,0.7]) for Alpha; 1,493 (0.7% [0.6,0.7]) for Delta and 10,709 (4.4% [4.3,4.5]) for Omicron (Table S1).
The proportion of swab positive individuals reporting any of 26 symptoms was highest in those infected with BA.2 (75.9% [74.4,77.2], compared with 70% [68.3,71.6] in those with BA.1, 63.8% [61.3,66.2] in those with Delta, 54.7%, [52.7,56.8] in those with Alpha and 45% [43.3,46.8] in those with wild-type) (Table S2). Background prevalence of symptoms was also highest during January – March 2022, when Omicron dominated: 21.9%, [21.7,22.0] of all respondents reported one or more symptoms, compared with 13.5% [13.4,13.5] during the wild-type period (Table S1).
Those infected with BA.2 reported an average of 6.02 symptoms in the week prior to PCR testing, compared with 2.70, 3.38, 4.63 and 4.63 for wild-type, Alpha, Delta and BA.1 respectively (Table S2). A larger proportion of people with BA.2 reported that their symptoms had affected their ability to carry out day-to-day activities ‘a lot’ (17.6% [16.3,18.8]) compared with those infected with BA.1 (10.7% [9.6,11.9]) or Delta (10.5%, [9.1,12.2]) (Table S2).
All symptoms were positively associated with swab positivity for all variants (Figure 2, Table S3). The odds ratio for swab positivity of ‘any of 26 symptoms’ was highest for BA.2 (OR=12.9 [11.9,14.0], compared with 5.16 [4.79,5.55], 6.01 [5.12,7.06], 9.53 [8.55,10.6] and 9.61 [8.82,10.5] for wild-type, Alpha, Delta and BA.1, respectively) (Table S3, Figure 2).
Unlike for wild-type, Alpha, and Delta, where the highest odds ratios for swab positivity were for loss or change of sense of smell (ORs 49.7 [44.3,55.7], 37.8 [28.6,50.0] and 73.4 [64.2,83.9] respectively) or taste (ORs 35.9 [31.9,40.4], 38.9 [29.9,50.6] and 68.1 [59.4,78.0] respectively), for BA.1 and BA.2, influenza-like and cold-like symptoms were relatively more predictive of swab positivity, and loss or change of sense of smell or taste relatively less so. Within BA.1 and BA.2, the highest odds ratio of all symptoms was for fever: ORs were 18.4 [16.5,20.5] in BA.1 and 30.2 [27.7,33.0] in BA.2, compared with 12.9 [11.1,15.1] and 17.2 [15.1,19.5] respectively for loss or change of sense of smell and 16.0 [13.9,18.5] and 21.3 [18.9,24.0] respectively for loss or change of sense of taste (Figure 2, Table S3).
Multivariable analysis for variable selection
We used LASSO penalised logistic regression to identify parsimonious symptom sets selected as jointly and positively predictive of swab positivity for each variant (Figure 3); this method takes into account differences in symptom cooccurrence by variant (Figure S3). Loss or change of sense of taste, new persistent cough, and fever were selected for each variant. Notably, cold-like symptoms of runny nose, sore throat, sneezing and hoarse voice were only selected for Omicron (BA.1 and BA.2).
Omicron (BA.1 and BA.2)
Comparing symptoms for BA.2 vs BA.1 using (adjusted and matched) logistic regression (see Methods), infection with BA.2 was positively associated with chest pain, severe fatigue, runny nose, muscle aches, sneezing, fever, chills, tiredness, blocked nose and headache (in both models); in unmatched analysis, infection with BA.2 is further associated with further associated with sore eyes, appetite loss and new persistent cough.
In a triple-vaccinated subgroup of 4,834 swab-positive individuals with BA.1 or BA.2, those infected with BA.2 were 64% more likely to report symptoms that interfered with their ability to carry out day-to-day activities ‘a lot’ (OR 1.64 [1.22, 2.19]) vs ‘a little’, ‘not at all’, or not reporting any symptoms, after adjustment for age group, sex, round, and time since third vaccine (Table 1). In the same models, men were 40% less likely than women to report symptoms that interfered with their ability to carry out day-to-day activities ‘a lot’ (OR 0.60, [0.51,0.72]).
Ct values
Ct values were lower for BA.2 than BA.1 (Figure S1). This may reflect the timing of the sampling with respect to the growth of the variant since more recent infections will tend to have lower Ct values (see Table S2 and Supplementary Figure S5, which show that mean time since symptom onset was lower in BA.2 than for BA.1). Symptomatic individuals had lower Ct values than asymptomatic people. In linear regression models among swab positive individuals in rounds 17–19, for each of the 26 surveyed symptoms, symptom reporting was associated with a lower Ct value. The lowest adjusted Ct values were for influenza-like or cold-like symptoms: fever, chills, sore throat, muscle aches, runny nose, sneezing and headache (Figure 4), which frequently co-occurred (Figure S3). With the exception of fever, these symptoms were also commonly reported as the first symptom among symptomatic swab positives (Figure S4, Table S2).
Discussion
In this study of more than 1.5 million people randomly selected from the population in England, we show a change in symptom reporting associated with Omicron compared with previous variants, and within Omicron for BA.2 vs BA.1. This may reflect changes in the underlying pathophysiology associated with different variants, affecting receptor binding, cell entry and host response, against a background of varying levels of population immunity (both from natural infection and vaccine-induced).16–18
We found that loss or change of sense of smell and taste were less predictive of swab positivity for Omicron than for other variants, and that cold-like symptoms were more predictive for Omicron than for previous variants. Both these findings were consistent with previous research.5,19,20 It is of interest that infections with Omicron variants are not as strongly associated with anosmia. The loss of sense of smell and taste following infection with early variants of SARS-CoV-2 results from the downregulated expression of olfactory receptors.21 It is likely that changes in the sequence of viral genes that regulate host responses in Omicron do not result in this effect. Detailed transcriptomic studies in animal models and humans may help to pinpoint the mechanisms involved.
Comparing Omicron BA.2 with BA.1, we found that those with BA.2 were more likely to be symptomatic, reported more symptoms on average, were more likely to report a number of influenza-like and cold-like symptoms, and were more likely to report that their symptoms affected their day-to-day activities ‘a lot’. This last finding was robust to adjustment for time since third vaccine dose and is therefore unlikely to be explained by waning immunity from vaccination.
From 1 April 2022 the UK government moved to a policy of ‘living with COVID’.22 With the lifting of restrictions and access to free testing limited, identifying individuals who are particularly likely to be infectious on the basis of symptoms alone may help reduce ongoing transmission of SARS-CoV-2. We showed that reporting fever, chills, sore throat, muscle aches, runny nose, sneezing and headache was associated with the lowest adjusted Ct values and therefore most likely to be indicative of higher viral load and increased infectiousness.
Our study has limitations. Response rates varied between 11.7% and 26.5% for rounds 2–19, so the samples may not be fully representative of, or results fully generalisible to, the population. Nevertheless, our random community sampling procedure included individuals from all of the 315 lower tier local authority areas in England in each round, ensuring wide geographical coverage and socio-economic and demographic diversity. Of those who provided valid swabs and consented to linkage in rounds 1–19 of REACT-1 (2,191,597 people in total), approximately 3% (65,915 people) participated in more than one round. On this basis, a correction factor of 1.015 could therefore be applied to the standard error estimates. We are not able to definitively identify instances of participation in more than one round among those who did not consent to linkage. However, because the consent-based estimate of the correction factor is so close to one, we feel confident reporting uncorrected SEs and confidence intervals. The symptoms surveyed were not exhaustive but, while not specific to COVID-19, were all shown to be predictive of SARS-CoV-2 swab positivity. Our analysis covers a period of 22 months, during which time background levels of natural and vaccine-acquired immunity varied substantially, making it difficult to differentiate the effect of viral mutations from the impact of vaccines and prior infection.18 As REACT-1 data collection was non-continuous, we may have captured different stages of epidemic growth across variants, which may have differentially affected symptom reporting at different times.
In summary, we have detected changes in symptom profiles reported during nearly two years of the epidemic in England, reflecting the emergence of different variants over that period. Most recently, infection with Omicron is associated with lower reporting of loss or change of sense of smell and taste, and higher reporting of cold-like and influenza-like symptoms. Sequence-confirmed BA.2 was associated with reporting of more symptoms and greater disruption to daily activity compared with BA.1. As routine testing becomes more limited in many countries, and as new variants emerge, understanding the symptom profiles which can identify individuals with a higher risk of transmission will become increasingly important.
Data Availability
Access to REACT-1 individual-level data is restricted to protect participants' anonymity. Summary statistics, descriptive tables, and code from the current REACT-1 study are available at https://github.com/mrc-ide/reactidd (doi 10.5281/zenodo.6550327). REACT-1 study materials are available for each round at https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/react-1-study-materials/ Sequence read data are available without restriction from the European Nucleotide Archive at https://www.ebi.ac.uk/ena/browser/view/PRJEB37886, and consensus genome sequences are available from the Global initiative on sharing all influenza data (GISAID).
https://github.com/mrc-ide/reactidd/tree/master/inst/extdata/
Funding
The study was funded by the Department of Health and Social Care in England. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of this manuscript. PE is Director of the Medical Research Council (MRC) Centre for Environment and Health (MR/L01341X/1, MR/S019669/1). PE acknowledges support from Health Data Research UK (HDR UK); the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; NIHR Health Protection Research Units in Chemical and Radiation Threats and Hazards, and Environmental Exposures and Health; the British Heart Foundation Centre for Research Excellence at Imperial College London (RE/18/4/34215); and the UK Dementia Research Institute at Imperial College London (MC_PC_17114). HW acknowledges support from an NIHR Senior Investigator Award, the Wellcome Trust (205456/Z/16/Z), and the NIHR Applied Research Collaboration (ARC) North West London. JE is an NIHR academic clinical fellow in infectious diseases. GC is supported by an NIHR Professorship. CAD acknowledges support from the MRC Centre for Global Infectious Disease Analysis, the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and the NIHR-funded Vaccine Efficacy Evaluation for Priority Emerging Diseases (PR-OD-1017-20007). MC-H and BB acknowledge support from Cancer Research UK, Population Research Committee Project grant ‘Mechanomics’ (grant No 22184 to MC-H). MC-H acknowledges support from the H2020-EXPANSE (Horizon 2020 grant No 874627) and H2020-LongITools (Horizon 2020 grant No 874739).
Ethics
We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787). Notification of favorable opinion and brief summary of the protocol are available here: https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/react1-covid-19-uph/
Public involvement
A Public Advisory Panel provides input into the design, conduct, and dissemination of the REACT research program.
Data availability
Access to REACT-1 individual-level data is restricted to protect participants’ anonymity. Summary statistics, descriptive tables, and code from the current REACT-1 study are available at https://github.com/mrc-ide/reactidd (doi 10.5281/zenodo.6550327). REACT-1 study materials are available for each round at https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/react-1-study-materials/Sequence read data are available without restriction from the European Nucleotide Archive at https://www.ebi.ac.uk/ena/browser/view/PRJEB37886, and consensus genome sequences are available from the Global initiative on sharing all influenza data (GISAID)23.
Supplementary material
Supplementary methods
Assessing model performance in variable selection
To quantify the gain in predictive accuracy conferred by each selected symptom, un-penalised logistic models were successively re-fit on 80% subsamples of the holdout data, adding each symptom in order of decreasing selection proportion, and evaluated on the remainder of the holdout data (20%). Age, sex and vaccination status were forced in as predictors in all models. For each set of predictors, the procedure was repeated 100 times with different splits of the holdout data. As in the variable selection, regression coefficients were constrained to non-negativity in the re-fit models.
Footnotes
↵* Joint first author